Typewriter Therapeutics
Typewriter Therapeutics, Inc.
Home - Typewriter Therapeutics
typewritertx.com · Cambridge, MA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$56.3M of $56.3M
Filed2026-09-21
Days since filing12
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2026-01-08
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Matthew StantonExecutive Officer · Director
- Kenneth HorneDirector
- Laura TadvalkarDirector
- Mikael DolstonDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged100% sold8.8 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-221
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- ScientistOCT 1open 3 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.